Overview

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
Phase:
Phase 3
Details
Lead Sponsor:
Threshold Pharmaceuticals
Collaborator:
PRA Health Sciences
Treatments:
Lonidamine